alfuzosin hydrochloride / Generic mfg. - LARVOL DELTA

The Discovery of α-Adrenoceptor Antagonists as a Potential New Treatment Option for Uveal Melanoma. (PubMed, Biomolecules) - "Drug screening with UM spheroids revealed that prazosin and doxazosin dose-dependently reduced viability, whereas terazosin, alfuzosin, silodosin, tamsulosin, and phenoxybenzamine were found to be inefficient. This suggests a tumor-preventive effect through the blockade of α1A-AR. The present study highlights the responses of UM spheroids to α-AR antagonists and demonstrates that prazosin, doxazosin, or RS17053 may be a treatment option for preventing UM tumor recurrence or metastasis."

Journal • Eye Cancer • Hepatocellular Cancer • Melanoma • Ocular Melanoma • Oncology • Solid Tumor • Uveal Melanoma • AR

Comparison of the First Dose and Efficacy of Alfuzosin, Tamsulosin and Silodosin in the Treatment of Benign Prostatic Hyperplasia. (PubMed, Arch Esp Urol) - "Silodosin provided the most rapid symptomatic improvement following initial administration, likely due to its high α1A-receptor selectivity. However, by the third month, all three agents showed similar clinical efficacy, supporting their use as viable treatment options tailored to patient-specific needs."

Clinical • Journal • Retrospective data • Benign Prostatic Hyperplasia

Efficacy of Hexanic Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Multicenter Randomized Study. (PubMed, Prostate) - "The combination of HESr and alfuzosin was significantly more effective than alfuzosin monotherapy in relieving LUTS, with greater benefits from Month 3 onward. Qmax and nocturia also showed greater, although mild, improvements with combination therapy. Sexual function outcomes were comparable between groups. High adherence and real-world applicability support the clinical value of this combination in managing BPH-related LUTS."

Journal • Benign Prostatic Hyperplasia • Inflammation

Novel Compounds in Targeting the α1-adrenoceptor for Antihypertensive Therapy. (PubMed, Cardiovasc Hematol Agents Med Chem) - "Terazosin, doxazosin, tamsulosin, and alfuzosin are examples of α1-adrenoceptor antagonists that have antihypertensive properties; however, they are linked to considerable side effects, including headaches, dizziness, reproductive problems, and postural hypotension. In the last several years, a number of novel α1-adrenergic antagonists have been synthesised by modifications of various pharmacophores such as Isochroman-4-one, Quinazolines, Piperazine, and Quinazoline-triazole, etc. The present review highlights recently synthesized α1-adrenoceptor antagonists for the management of hypertension, and emphasizes their structure-activity relationship and subtype selectivity."

Journal • Cardiovascular • Hypertension • Hypotension • Myocardial Infarction • Pain

Electromotive Drug Administration in the Porcine Ureter: First In Vivo Application for Ureteral Dilation. (PubMed, J Endourol) - "Neither aminophylline nor isoproterenol with EMDA resulted in a significant increase in ureteral size compared with their respective NS controls (aminophylline vs NS, 0.3 Fr vs -0.6 Fr, p = 0.344; isoproterenol vs NS, 0.1 Fr vs -0.4 Fr, p = 0.125). In this first report, EMDA-mediated in vivo delivery of alfuzosin into the porcine ureter acutely increased ureteral distensibility."

Journal • Preclinical

Prophylactic alpha-blockers for prevention of post-operative urinary retention after total mesorectal excision for cancer: A prospective multicenter study from the GRECCAR group (ESCP 2025) - "LOS was significantly shorter with Alfuzosin compared to both standard care(6 days [2-60] vs. 10 days [4-72],p<0.001) and Silodosin(8 days [5–40],p<0.001). Conclusion Prophylactic Alfuzosin significantly reduces post-operative urinary retention and re-catheterization rate after TME with a shorter LOS.This Alfuzosin protocol should be implemented in early rehabilitation programs in order to improve postoperative outcomes after rectal surgery."

Clinical • Benign Prostatic Hyperplasia • Colorectal Cancer • Oncology • Prostate Cancer • Rectal Cancer • Solid Tumor

Prostatitis: A Review. (PubMed, JAMA) - "First-line therapy for chronic bacterial prostatitis is a minimum 4-week course of levofloxacin or ciprofloxacin...First-line oral therapy for CP/CPPS with urinary symptoms is α-blockers (eg, tamsulosin, alfuzosin; ΔNIH-CPSI score difference vs placebo = -10.8 to -4.8). Other oral therapies are associated with modest changes in NIH-CPSI score compared with placebo, including anti-inflammatory drugs (eg, ibuprofen; ΔNIH-CPSI score difference = -2.5 to -1.7), pregabalin (ΔNIH-CPSI score difference = -2.4), and pollen extract (ΔNIH-CPSI score difference = -2.49). Prostatitis includes acute bacterial prostatitis, chronic bacterial prostatitis, and CP/CPPS, each of which is diagnosed and treated differently. First-line treatments are broad-spectrum antibiotics for acute bacterial prostatitis (such as piperacillin-tazobactam, ceftriaxone, or ciprofloxacin), at least 4 weeks of fluoroquinolones for chronic bacterial prostatitis, and α-blockers for CP/CPPS with urinary symptoms."

Journal • Gynecology • Infectious Disease • Musculoskeletal Pain • Nephrology • Oncology • Pain

Alfuzosin and Mirabegron for Double-J Stent Symptoms (clinicaltrials.gov) - P=N/A | N=100 | Completed | Sponsor: University of Gaziantep

New trial

An eco-friendly HPLC method for the sustainable analysis of the newly approved combinations of Alfuzosin and Tamsulosin, with Tadalafil in organic-solvent-free mixed-micellar systems. (PubMed, Analyst) - "Greenness of the method was assessed using the Analytical GREEnness metric approach (AGREE), and the blueness was assessed using blue applicability grade index (BAGI), with scores of 0.76 and 82.5, respectively. These scores underline the superiority of the proposed procedure over previously reported methods."

Journal • Benign Prostatic Hyperplasia • Urology

Electromotive Drug Administration (EMDA) in the Porcine Ureter: First Report of In Vivo Ureteral Dilation Following Alfuzosin Infusion (AUA 2025) - "Ureteral infusion of AFZ using EMDA resulted in higher levels of drug penetration and a significant increase in porcine ureteral distensibility."

Preclinical

The Beneficial Effects of Alpha-Blockers, Antimuscarinics, Beta 3-Agonist, and PDE5-Inhibitors for Ureteral Stent-Related Discomfort: A Systematic Review and Meta-Analysis from KSER Update Series. (PubMed, Medicina (Kaunas)) - "This study utilized a network meta-analysis to evaluate stent-related discomfort (SRD) in patients with alpha-blockers (alfuzosin, tamsulosin, and silodosin), antimuscarinics (solifenacin), beta 3-agonists (mirabegron), and phosphodiesterase 5-inhibitors (tadalafil) versus a placebo. Compared with the placebo, solifenacin, tamsulosin, and alfuzosin significantly decreased the USS. In our study, solifenacin may be considered the most effective medication for SRD."

Clinical • Journal • Retrospective data • Review • Renal Calculi • Urolithiasis • Urology

α-Adrenoreceptor blocker phentolamine inhibits voltage-gated sodium channels via the local anaesthetic binding site. (PubMed, Br J Pharmacol) - "Phentolamine blocks voltage-gated sodium channels via the local anaesthetic receptor site. This may conflict with its current indication as an antidote for local anaesthetics. We propose alternative α-adrenoreceptor antagonists as possible candidates for local anaesthetic reversal because these are less potent inhibitors of both cardiac and neuronal voltage-gated sodium channels."

Journal • Anesthesia • Pain • NAV1

Drug-induced dementia: a pharmacovigilance analysis of the FAERS database. (PubMed, Expert Opin Drug Saf) - "Besides neurological drugs, the drugs with the highest number of reports are apixaban, valsartan and atorvastatin. We found that tamsulosin, alfuzosin, and megestrol may be associated with an increased risk of dementia, and further research is required to clarify these relationships. In clinical practice, it is important to monitor the cognitive status of patients when using drugs that may increase the risk of dementia."

Adverse events • Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Dementia

Alpha-adrenergic antagonists and iris dynamics: Challenges and solutions in cataract surgery. (PubMed, BMC Ophthalmol) - "α1-ARAs have implications for pupil size regulation and surgical procedures involving the eye. Tamsulosin is more potent than alfuzosin in inducing IFIS. Systemic α1-ARAs lower values of DMR thickness, DMR/SMR ratio and reduces pupillary diameter. Therefore, ophthalmologists, primary care physicians, urologists, and patients should be aware of the potential difficulties that these drugs pose for cataract surgery."

Journal • Surgery • Benign Prostatic Hyperplasia • Cardiovascular • Cataract • Hypertension • Ophthalmology • Urology • ADRA1B

Association Between Alpha-1 Adrenoreceptor Antagonist Use and Cognitive Impairment: A Systematic Review. (PubMed, Int Neurourol J) - "Tamsulosin was associated with no cognitive dysfunction in 2 RCTs, increased risk for dementia in 2 non-RCTs, no change in cognition in 1 non-RCT, and decreased risk for dementia in 1 non-RCT. Among 3 non-RCTs analyzing alfuzosin, it was associated with decreased risk of or no association with dementia in 2 studies and increased risk for dementia in 1 study. Doxazosin, prazosin, and terazosin were neutral or showed a negative risk for dementia...Considering the existing literature, it is appropriate to use α1-AR antagonists without concern for cognitive dysfunction. Future research, through robust study designs considering the multifactorial nature of cognitive dysfunction, is required to further evaluate this association."

Journal • Review • Alzheimer's Disease • Benign Prostatic Hyperplasia • Cardiovascular • CNS Disorders • Cognitive Disorders • Dementia • Hypertension • ADRA1B

Clinical features and management approaches for Urinary Incontinence in Older Adults: Evidence from Three Hospitals in Qatar. (PubMed, Nepal J Epidemiol) - "Solifenacin (24.9%), Tolterodine (4.1%), and Oxybutynin (1.1%) were the most commonly administered anticholinergic drugs, while Tamsulosin (82.9%), Alfuzosin (14.5%), and Doxazosin (1.7%) were the most frequently prescribed alpha-blockers. This study also highlights the need for thorough documentation of the diagnosis and reasons for improving the standards of patient care. The findings of this study provide important information that can be used to design medication management methods for enhancing patient outcomes."

Journal • Geriatric Disorders • Urinary Incontinence • Urology

Tamsulosin use in benign prostatic hyperplasia and risks of Parkinson's disease, Alzheimer's disease and mortality: An observational cohort study of elderly Medicare enrollees. (PubMed, PLoS One) - "The study analyzed 1.1 million patients for a mean follow-up period of 3.1 years from being prescribed one of the study drugs. For all outcomes, patients on tamsulosin were used as the reference for comparison. For mortality, alfuzosin was associated with 27% risk reduction (HR 0.73, 95%CI 0.68-0.78), and doxazosin with 6% risk reduction (HR 0.94, 95%CI 0.91-0.97). For Parkinson's disease, terazosin was associated with 26% risk reduction (HR 0.74, 95%CI 0.66-0.83), and doxazosin with 21% risk reduction (HR 0.79, 95%CI 0.72-0.88). For Alzheimer's disease, terazosin was associated with 27% risk reduction (HR 0.73, 95%CI 0.65-0.82), and doxazosin with 16% risk reduction (HR 0.84, 95%CI 0.76-0.92). Tadalafil was associated with risk reduction (27-40%) in all 3 outcomes. More research is needed to elucidate the underlying mechanisms of these observations. Given the availability of safer alternatives for treating benign prostatic hyperplasia, caution should be..."

Journal • Medicare • Observational data • Reimbursement • US reimbursement • Alzheimer's Disease • Benign Prostatic Hyperplasia • CNS Disorders • Movement Disorders • Parkinson's Disease

Synthesis of diversely substituted quinazoline-2,4(1H,3H)-diones by cyclization of tert-butyl (2-cyanoaryl)carbamates. (PubMed, Org Biomol Chem) - "This strategy can be utilized for the simplified synthesis of goshuyuamide II and an alkaloid isolated from Zanthoxylum arborescens in good yields. This method was also applied to the synthesis of quinazoline-2,4(1H,3H)-diones that are precursors of medicinally important compounds: alfuzosin, terazosin, prazosin, IAAP, doxazosin, FK 366 (zenarestat) and KF31327."

Journal

Association of Terazosin, Doxazosin, or Alfuzosin Use and Risk of Dementia With Lewy Bodies in Men. (PubMed, Neurology) - "We find an association in men who are taking Tz/Dz/Az and a lower hazard of DLB compared with similar men taking other medications. When combined with the literature of Tz/Dz/Az on Parkinson disease, our findings suggest that glycolysis-enhancing drugs may be broadly protective in neurodegenerative synucleinopathies. A future randomized trial is required to assess these associations for causality."

Journal • Alzheimer's Disease • Benign Prostatic Hyperplasia • CNS Disorders • Cognitive Disorders • Dementia • Lewy Body Disease • Movement Disorders • Parkinson's Disease

Risk of Parkinson's disease among users of alpha-adrenergic receptor antagonists: a systematic review and meta-analysis. (PubMed, Ann Med Surg (Lond)) - "The objective of the study is to compare the risk of Parkinson's disease (PD) between terazosin/alfuzosin/doxazosin (TZ/AZ/DZ) users and tamsulosin users. The risk of occurrence of PD was significantly lower in patients taking TZ/AZ/DZ than tamsulosin (n= 610,363, HR = 0.82, 95% CI = 0.71-0.94, P = 0.01; I2 = 87.4%). This meta-analysis demonstrated that patients with BPH who take TZ/AZ/DZ have a lower risk for developing PD than those who take tamsulosin."

Journal • Retrospective data • Review • Benign Prostatic Hyperplasia • CNS Disorders • Movement Disorders • Parkinson's Disease • ADRA1B

A MOF-Templated Double-Shelled Co3O4/NiCo2O4 Nanocomposite for Electrochemical Detection of Alfuzosin. (PubMed, Nanomaterials (Basel)) - "The sensor was successfully applied to determine the AFZ in pharmaceutical tablets and human serum samples, with satisfactory recoveries. Our results suggest that the double-shelled Co3O4/NiCo2O4 nanocomposite is a promising material for the fabrication of electrochemical sensors for AFZ detection."

Journal • Benign Prostatic Hyperplasia

Utilization of absorbance subtraction and ratio difference green spectrophotometric methods for the quantification of alfuzosin hydrochloride and tadalafil in their binary mixture. (PubMed, BMC Chem) - "The methods used were verified in accordance with the recommendations of the ICH and demonstrated adequate linear regression in working ranges of 1-15 µg/mL for alfuzosin hydrochloride and 3-40 µg/mL for tadalafil. The methods were accurate, precise, and selectively employed to quantify alfuzosin hydrochloride and tadalafil in their combined tablets."

Journal • Benign Prostatic Hyperplasia

In-Vivo Acute Ureteral Dilation using Electromotive Drug Administration (EMDA) in the Porcine Ureter (AUA 2024) - "In each of six pigs, in one ureter, an EMDA catheter was activated while alfuzosin 10 mg, isoproterenol 1 mg, or aminophylline 500 mg each diluted in 100 ml sterile water were infused at 5 ml/min for 20 minutes. In the porcine ureter, EMDA administration of alfuzosin significantly increased ureteral distensibility."

Preclinical • Urolithiasis

BE24-005: Multiple Dose, Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets Under Fed Conditions (clinicaltrials.gov) - P1 | N=44 | Not yet recruiting | Sponsor: Pharma Nueva

New P1 trial

Effect of different alpha-receptor antagonists on metabolic parameters: a head-to-head comparison. (PubMed, Int Urol Nephrol) - "Although these results do not support previous findings that tamsulosin has adverse effects on metabolic parameters, they suggest that doxazosin treatment may be a reason for preference in patients with BPH or LUTS accompanied by metabolic disorder."

Head-to-Head • Journal • Benign Prostatic Hyperplasia • Dyslipidemia • Metabolic Disorders • ADRA1B